UNSPSC 51201811: Thalidomide

This classification denotes an indole compound and immunosuppressant with the molecular formula C13H10N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4Z8R6ORS6L, chemically known as 2,6-dioxo-3-phthalimidopiperidine but generally known as thalidomide, which bears US NIH Compound Identifier 5426. European Medicines Agency schedules Thalidomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10958MIG.

UNSPSC 51201811 Thalidomide is a Commodity code that covers pharmaceutical preparations, but the recent state and local procurement activity under this code does not align with its nominal scope. The Mississippi State Department of Health posted a sole source procurement notice on July 13, 2026 for Yellow Fever Vaccine from Sanofi Pasteur, Inc.—a vaccine product falling outside thalidomide's therapeutic class and typical procurement patterns. The notice invites objections to sole source classification through August 3, 2026, and requires any challenger to demonstrate that an alternative vendor can supply the vaccine. If substantiated objections are received, the department will conduct a competitive bid or selection process; if the department prevails in establishing exclusive-source status, it must appeal to the Public Procurement Review Board and carry the burden of proof.

The available record shows minimal recent activity under this code in the state and local market, and the single posted opportunity appears to be a misclassification—the Yellow Fever Vaccine solicitation does not fall within thalidomide's pharmaceutical scope. No quantity, contract term, estimated value, or pricing information is disclosed in the notice. Firms evaluating this code should note that state and local procurement activity is not currently robust here and that the posted opportunity does not represent typical procurement under the code's nominal classification.